2021

Grbčić, P. Čupić, D.F.; Gamberi, T.; Pavelić, S.K.; Sedić, M. Proteomic Profiling of BRAFV600E Mutant Colon Cancer Cells Reveals the Involvement of Nucleophosmin/c-Myc Axis in Modulating the Response and Resistance to BRAF Inhibition by Vemurafenib. Int. J. Mol. Sci. 2021, 22(12), 6174, https://doi.org/10.3390/ijms22126174  (Q1) IF 5.923

2020

Grbčić P, Sedić M. Sphingosine 1-Phosphate Signaling and Metabolism in Chemoprevention and Chemoresistance in Colon Cancer. Molecules. 2020 May 23;25(10):2436. doi: 10.3390/molecules25102436. (Q1) IF 4.411

Rahman S, Wittine K, Sedić M, Markova-Car EP. Small Molecules Targeting Biological Clock; A Novel Prospective for Anti-Cancer Drugs. Molecules. 2020 Oct 26;25(21):4937. doi: 10.3390/molecules25214937. (Q1) IF 4.411

Visentin S, Sedić M, Pavelić SK, Pavelić K. Targeting Tumour Metastasis: The Emerging Role of Nanotechnology. Curr Med Chem. 2020;27(8):1367-1381. doi:10.2174/0929867326666181220095343. (Q1) IF 4.53

2019

Grbčić P, Car EPM, Sedić M. Targeting Ceramide Metabolism in Hepatocellular Carcinoma: New Points for Therapeutic Intervention.Curr Med Chem. 2019; 27(39): 6611 – 6627. DOI: 10.2174/0929867326666190911115722. (Q1) IF 4.184  

Sedić M, Grbčić P, Pavelić SK. Bioactive Sphingolipids as Biomarkers Predictive of Disease Severity and Treatment Response in Cancer: Current Status and Translational Challenges. Anticancer Res. 2019 Jan;39(1):41-56. doi: 10.21873/anticanres.13078. (Q2) 1.994